Journal article
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial
JR Petrie, N Chaturvedi, I Ford, I Hramiak, AD Hughes, AJ Jenkins, B E. Klein, R Klein, TC Ooi, P Rossing, N Sattar, CDA Stehouwer, HM Colhoun, S Kean, E Thomson, L Gillespie, J Gibb, N Greenlaw, A Keech, K March Show all
Diabetes Obesity and Metabolism | WILEY | Published : 2017
DOI: 10.1111/dom.12840
Abstract
Aims: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D. Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 specified CV ris..
View full abstractGrants
Awarded by Juvenile Diabetes Research Foundation
Funding Acknowledgements
The REMOVAL trial is funded by Strategic Research Award 17-2011-272 from the Juvenile Diabetes Research Foundation. Study medication was donated and shipped to sites free of charge by agreement with Merck KGaA (Darmstadt, Germany). ENDOPAT measurements were part-funded via a partnership agreement with Itamar Medical (Caesarea, Israel).